front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |review |
LCS: Assesses
common symptoms of lung cancer Tightness in chest Shortness of breath Coughing TOI: Physical (“do you feel ill”) + Functional (“Able to work/Sleep”) + LCS Focussed on the LCS and TOI b/c they are the most clinically relevant QOL endpoints in lung cancer trials. Higher scores on both represent better function or fewer symptoms. Change scores: We used the 12 week follow-up (beginning of the 5th cycle of treatment) since it provided an optimal balance between having sufficient time to note significant clinical change, without having excessive missing data due to mortality or progression. The change score is the 12 week assessment - baseline; so that positive scores represent improvements and negative scores represent declines in function. |